G2MC Appoints Interim Co-Chair as Founding Co-Chair Finishes Term

We are pleased to announce the appointment of Bruce Korf, MD, PhD (USA), as G2MC Interim Co-Chair for 2023. Dr. Korf has actively contributed to the growth of G2MC over the years, serving as a member on the Steering Committee, co-chair of the Education Working Group, and co-host of the past three G2MC international conferences. In his professional role, Dr. Korf serves as Wayne H. and Sara Crews Finley Endowed Chair in Medical Genetics and Associate Dean for Genomic Medicine at the University of Alabama at Birmingham (UAB) School of Medicine, Chief Genomics Officer at UAB Medicine, and Co-Director of the UAB-HudsonAlpha Center for Genomic Medicine. He will be joining co-chairs Catalina Lopez-Correa, MD, PhD (Canada), and George P. Patrinos, PhD (Greece), as he carries out his one-year term. 

Dr. Korf takes the place of former and founding G2MC co-chair, Geoffrey Ginsburg, MD, PhD (USA), who finished his term at the end of 2022. Dr. Ginsburg currently serves as Chief Medical and Scientific Officer with the All of Us Research Program at the National Institutes of Health, was Professor of Medicine (now Adjunct Professor of Medicine), Pathology and Biomedical Engineering at Duke University. Dr. Ginsburg is the founder of the Global Genomics Medicine Collaborative (G2MC, now GGMC) and served as president and co-chair of G2MC since its inception in 2016. 

“New leadership brings new ideas and fresh energy,” said Dr. Ginsburg. “I’m looking forward to Bruce’s leadership alongside Catalina and George, and I’m proud of what we have accomplished thus far, and thankful for the opportunity to take part in this growing and exciting organization.” 

We sincerely thank Dr. Ginsburg for his service and commitment to establishing and growing the G2MC organization, and we are pleased that he will remain actively involved with G2MC beyond his co-chair term. 

We are grateful for Dr. Korf’s acceptance of the interim co-chair position. During this period, we hope to allow time for potential co-chair candidates to become more involved in G2MC activities, demonstrating their engagement, commitment, and leadership. It is also our commitment to ensure we are appointing leaders from diverse backgrounds and demographics, promoting inclusion and equity as we expand our global imprint.  

“During this interim period, I look forward to providing leadership and guidance alongside Catalina and George in an effort to grow and promote the organization,” said Dr. Korf. “Particularly, it is my mission to involve people from diverse backgrounds around the world where genomic medicine is not yet well developed, with the goal to identify potential members and leaders who can represent lesser-served areas, allowing us to help drive genomic medicine implementation in these areas.”

Please join us as we welcome Dr. Korf to the interim co-chair role and thank Dr. Ginsburg for his immense contributions to the organization. We look forward to the process of electing a permanent co-chair to begin in 2024.